The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy

British Journal of Cancer

Volumn 102, Issue 3, 2010, Pages 553-560

  Nutt, J E ^a   Razak, A R A ^a,c   O'Toole, K ^a   Black, F ^b   Quinn, A E ^a   Calvert, A H ^a,c   Plummer, E R ^a,c   Lunec, J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Royal Victoria Inf Irmary ^*  (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Cell lines; Folate receptor a; Immunohistochemistry; Mesothelioma; Pemetrexed

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; FOLIC ACID; PARAFFIN; PEMETREXED; PROTON COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; OUTCOME ASSESSMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARRIER PROTEINS; CELL LINE, TUMOR; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL NEOPLASMS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 76349104827     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605501     Document Type: Article

References (29)

1. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D (2001) The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121: 225-233
2. Cakir C, Gulluoglu MG, Yilmazbayhan D (2006) Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 38: 10-15
3. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12: 808-815
4. Chattopadhyay S, Wang Y, Zhao R, Goldman ID (2004) Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 10: 7986-7993
5. Chattopadhyay S, Zhao R, Tsai E, Schramm VL, Goldman ID (2006) The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol Cancer Ther 5: 2549-2555
6. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6: 363-373
7. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731
8. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92: 587-593
9. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20: 3533-3544
10. Kamen BA, Smith AK (2004) A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56: 1085-1097
11. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119: 243-250
12. Khokhar NZ, Lam AFY, Rusch VW, Sirotnak FM (2002) Despite some expression of folate receptor alpha in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated. J Thorac Cardiovasc Surg 123: 862-868
13. Klominek J, Robert KH, Hjerpe A, Wickstrom B, Gahrton G (1989) Serum-dependent growth patterns of two, newly established human meso-thelioma cell lines. Cancer Res 49: 6118-6122
14. Mantovani LT, Miotti S, Menard S, Canevari S, Raspagliesi F, Bottini C, Bottero F, Colnaghi MI (1994) Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 30A: 363-369
15. Min SH, Goldman ID, Zhao R (2008) Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed. Cancer Chemother Pharmacol 61: 819-827
16. Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F (2008) Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 54: 166-175
17. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J (2004) Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 90: 1679-1685
18. Racanelli AC, Rothbart SB, Heyer CL, Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69: 5467-5474
19. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
21. Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J (2007) A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma 26: 281-288
22. Theti DS, Jackman AL (2004) The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 10: 1080-1089
23. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74: 193-198
24. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354
25. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644
26. Wang Y, Zhao R, Chattopadhyay S, Goldman ID (2003) A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate pemetrexed. Cancer Res 63: 7004-7004
27. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski Jr VR, Kamen BA (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52: 3396-3401
28. Whetstine JR, Flatley RM, Matherly LH (2002) The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 367: 629-640
29. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74: 854-862